ArticleAmerican journal of translational research2026
Esomeprazole plus trimebutine maleate improves symptoms, esophageal function, and acid control without increasing risks in elderly GERD: a real-world retrospective study.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesElderly patients with gastroesophageal reflux disease (GERD) often exhibit inadequate response to proton pump inhibitor monotherapy due to accompanying motility disorders. This study evaluated the real-world safety and efficacy of esomeprazole (EMZ) combined with trimebutine maleate (TM) in this population.
methodsThis retrospective analysis included elderly GERD patients treated at The People's Hospital of Yongcheng from July 2022 to June 2025, categorized into EMZ monotherapy and EMZ + TM combination groups. Symptom efficacy and GerdQ scores were assessed at baseline, 4 and 8 weeks. Esophageal motility, 24-hour pH monitoring, inflammatory markers, liver and kidney function, and adverse reactions were evaluated before and after 8 weeks.
resultsA total of 184 patients were included (86 monotherapy, 98 combination). The combination group showed a higher total effective rate and lower GerdQ scores at 4 weeks and 8 weeks (all P<0.05). After 8 weeks, lower esophageal sphincter resting pressure, lower esophageal sphincter relaxation rate, and distal contractile integral were significantly higher, while ineffective contractions and total acid exposure time were significantly lower in the combination group (all P<0.05). Inflammatory markers were also significantly lower (all P<0.05). No significant differences in liver, kidney function, or adverse reactions were observed.
conclusionsAdding TM to EMZ improves symptom control, esophageal motility, acid exposure, and inflammatory markers in elderly GERD patients without compromising safety.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.